

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

b² Claim 1 (currently amended): A crystal ~~comprising~~ of an AR-LBD consisting of amino acids 13 through 258 of SEQ ID NO:1 complexed with ~~[[and]]~~ AR-LBD ligand complex, wherein said crystal diffracts to at least 3 angstrom resolution and has a crystal stability within 5% of its unit cell dimensions belonging to the space group P212121 and having the unit cell dimensions $a = 56.03$ angstrom, $b = 66.27$ angstrom, and $c = 70.38$ angstrom.

Claims 2-10 (canceled)

Claim 11 (currently amended): ~~[[A]] The crystal of claim 1 that comprises a molecular complex of an AR-LBD and an AR-LBD ligand, wherein the AR-LBD has an AR-LBD ligand binding site defined by the structure coordinates of AR-LBD amino acids V685, L700, L701, S702, S703, L704, N705, E706, L707, G708, E709, Q711, A735, I737, Q738, Y739, S740, W741, M742, G743, L744, M745, V746, F747, A748, M749, G750, R752, Y763, F764, A765, L768, F770, M780, M787, I869, L873, H874, F876, T877 and F878 according to Table A.~~

Claim 12 (canceled)

Claim 13 (currently amended): ~~[[A]] The crystal of claim 1 that comprises a molecular complex of an AR-LBD and an AR-LBD ligand, wherein the AR-LBD has an AR-LBD ligand binding site defined by the structure coordinates of AR-LBD amino acids N705, Q711, R752, F764 and T877 according to Table A.~~

Claims 14-33 (canceled)